RETRACTED ARTICLE: Granisetron reduces postoperative nausea and vomiting throughout menstrual cycle

  • Yoshitaka Fujii
  • Hiroyoshi Tanaka
  • Hidenori Toyooka
Reports of Investigation



The incidence of postoperative nausea and vomiting (PONV) is influenced by menstruation. This study was undertaken to assess the efficacy of granisetron, a selective 5-hydroxytryptamine type 3 receptor antagonist, for preventing PONV in patients during two different phases of menstrual cycle.


One hundred twenty female patients undergoing general anaesthesia for major gynaecological surgery were divided according to the phase of menstrual cycle into two groups: day one to eight (menstrual) and day nine to end of the cycle (non-menstrual) groups. In a randomized, double-blind manner, the patients received placebo (saline) or 40μg·kg−1 granisetroniv immediately before the induction of anaesthesia. All patients received a standardized general and epidural anaesthesia and epidural morphine plus bupivacaine for postoperative analgesia. The incidence of PONV and other adverse events was recorded during the first 24 hr after anaesthesia.


The treatment groups were similar with respect to patient demographics, types of surgery, anaesthetics administered and analgesics used postoperatively. The incidence of PONV was 72% and 32% in patients during menstruation receiving placebo or granisetron (P < 0.05), and was 46% and 20% in those during non-menstruation, respectively (P < 0.05). No differences in the incidence of other adverse events were observed among the groups.


Granisetron was effective in reducing the incidence of PONV in both phases of the menstrual cycle studied.


Les menstruations influencent l’incidence des nausées et des vomissements postopératoires (NVPO). Cette étude visait à évaluer I’efficacité du granisetron, un antagoniste du récepteur de la 5-hydroxytryptamine de type 3, administré pour la prévention des NVPO pendant les différentes phases du cycle menstruel.


Cent vingt patientes programmées pour une chirurgie gynécologique majeure sous anesthésie générate ont été réparties en deux groupes déterminés par la phase de leur cycle menstruel: du premier au huitième jour («menstruel») et du neuvième jour à la fin du cycle («non menstruel»). En double aveugle et aléatoirement, les patientes ont reçu un placebo (du sol. phys.) ou 40μg·kg−1 de granisetroniv immédiatement avant I’induction de I’anesthésie. Toutes les patientes ont reçu une anesthésie générale ou épidurale standard et de la morphine épidurale avec ajout de bupivacaïne pour I’analgésie postopératoire. L’incidence des NVPO et des autres incidents a été enregistrée pendant 24 h après I’anesthésie.


Les deux groupes étaient identiques sur le plan de la démographie, du type de chirurgie, de I’anesthésie et des analgésiques administrés en postopératoire. L’incidence des NVPO a été respectivement de 72% et de 32% dans le groupe menstruel recevant le placebo et le granisetron (P < 0,05) et de 46% et de 20% dans le groupe non menstruel (P < 0,05). L’incidence des complications a été la même dans les deux groupes.


Le granisetron a réduit efficacement complications des NVPO pendant les deux phases du cycle menstruel.


  1. 1.
    Watcha MF, White PF. Postoperative nausea and vomiting. Its etiology, treatment, and prevention. Anesthesiology 1992;77: 162–84.PubMedCrossRefGoogle Scholar
  2. 2.
    Beattie WS, Lindblad T, Buckley DN, Forrest JB. The incidence of postoperative nausea and vomiting in women undergoing laparoscopy is influenced by the day of menstrual cycle. Can J Anaesth 1991; 38: 298–302.PubMedCrossRefGoogle Scholar
  3. 3.
    Beattie WS, Lindblad T, Buckley DN, Forrest JB. Menstruation increases the risk of nausca and vomiting after laparoscopy. A prospective randomized study. Anesthesiology 1993; 78: 272–6.PubMedCrossRefGoogle Scholar
  4. 4.
    Bermudez J, Boyle EA, Minter WD, Sanger GJ. The anti-emetic potential of the 5-hydroxytryptamine3 receptor antagonist BRL 43694. Br J Cancer 1988; 58: 644–50.PubMedCrossRefGoogle Scholar
  5. 5.
    Fujii Y, Tanaka H, Toyooka H. Reduction of postoperative nausea and vomiting with granisetron. Can J Anaesth 1994; 41: 291–4.PubMedCrossRefGoogle Scholar
  6. 6.
    Fujii Y, Tanaka H, Toyooka H. Optimal anti-emetic dose of granisetron for preventing postoperative nausea and vomiting. Can J Anaesth 1994; 41: 794–7.PubMedCrossRefGoogle Scholar
  7. 7.
    Fujii Y, Tanaka H, Toyooka H. Prevention of postoperative nausea and vomiting with granisetron: a randomized, double-blind comparison with droperidol. Can J Anaesth 1995; 42: 852–6.PubMedCrossRefGoogle Scholar
  8. 8.
    Leeser J, Lip H. Prevention of postoperative nausea and vomiting using ondansetron, a new, selective, 5-HT3 receptor antagonist. Anesth Analg 1991; 72: 751–5.PubMedCrossRefGoogle Scholar
  9. 9.
    Carmichael J, Cantwell BMJ, Edwards CM, et al. A pharmacokinetic study of granisetron (BRL 43694A), a selective 5-HT3 receptor antagonist: correlation with anti-emetic response. Cancer Chemother Pharmacol 1989; 24: 45–9.PubMedCrossRefGoogle Scholar
  10. 10.
    Furue H, Oota K, Taguchi T, Niitani H. Clinical evalution of granisetron against nausea and vomiting induced by anticancer drugs. (I) Optimal dose-finding study (Japanese). J Clin Ther Med 1990; 6: 49–61.Google Scholar

Copyright information

© Canadian Anesthesiologists 1997

Authors and Affiliations

  • Yoshitaka Fujii
    • 1
  • Hiroyoshi Tanaka
    • 1
  • Hidenori Toyooka
    • 1
    • 2
  1. 1.Department of AnaesthesiologyToride Kyodo General HospitalIbarakiJapan
  2. 2.The Department of AnaesthesiologyTsukuba University Institute of Clinical MedicineIbarakiJapan

Personalised recommendations